For more information or confidential assistance
800-306-3180
se habla español

Claimant Seeks Class Action Status for Talc Lawsuit

Premises liability lawyer Los Angeles
A plaintiff who recently filed a talcum powder lawsuit against Johnson & Johnson involving their talc-based products has also laid grounds for the possibility of a class action to be formed. The plaintiff in this case states that the hundreds and possibly thousands of women who have been diagnosed with ovarian cancer as... Read more »

Early Trials Selected for Growing Androgel Lawsuits

Eight Androgel lawsuits have been selected out of around 5,500 cases currently pending to serve as bellwether trials in the coordinated litigation. The bellwether trials are carefully selected to provide insight into how juries might respond to evidence and testimony in future trials. These early trials also can serve as... Read more »

LA Woman Files Taxotere Lawsuit over Hair Loss

Chemotherapy-related hair loss is common, with about 65% of chemo patients losing their hair. However, hair loss is a harrowing event; according to studies, nearly half of female chemo patients consider it to be the most traumatic part of chemo. The profound impact of hair loss is known to strike... Read more »

Talcum Powder Blamed for Deaths in Recent Lawsuit

Defendants Johnson & Johnson allegedly ignored the link between long-term talc powder use and ovarian cancer, claims a new joint lawsuit filed by 10 plaintiffs. The plaintiffs include six families of women who lost their lives to ovarian cancer that was allegedly caused by the long-term use of talc for... Read more »

New Study Highlights Nexium Dangers

Recent large scale epidemiological and retrospective studies have demonstrated links between the use of proton pump inhibitors (PPIs) and an increased risk of renal failure, myocardial infarction and dementia. On top of this, medical experts say that up to 70 percent of patients that take PPIs for treatment of heartburn... Read more »

FDA Invokana Study Finds Potential Amputation Link

FDA
The U.S. Food and Drug Administration has issued a new safety alert regarding the type 2 diabetes drug canagliflozin — Invokana and Invokamet. The Agency issued a safety announcement on May 18, notifying patients and the medical community that results of an ongoing clinical trial revealed a higher number of... Read more »